| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KLK6 |
| Uniprot No | Q92876 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-244aa |
| 氨基酸序列 | LVHGGPCDKTSHPYQAALYTSGHLLCGGVLIHPLWVLTAAHCKKPNLQVF LGKHNLRQRESSQEQSSVVRAVIHPDYDAASHDQDIMLLRLARPAKLSEL IQPLPLERDCSANTTSCHILGWGKTADGDFPDTIQCAYIHLVSREECEHA YPGQITQNMLCAGDEKYGKDSCQGDSGGPLVCGDHLRGLVSWGNIPCGSK EKPGVYTNVCRYTNWIQKTIQAK |
| 预测分子量 | 27 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **文献名称**: "The new human tissue kallikrein gene family: structure, function, and association to disease"
**作者**: Yousef GM, Diamandis EP
**摘要**: 该综述系统分析了KLK基因家族(包括KLK6)的结构与功能，探讨了KLK6重组蛋白的异源表达(如哺乳动物细胞系统)及其丝氨酸蛋白酶活性，并关联其在癌症中的潜在作用。
2. **文献名称**: "Human kallikrein gene 6 (KLK6) is expressed in breast carcinomas and correlates with metastatic phenotypes"
**作者**: Magklara A, Scorilas A, Lopez-Otin C, et al.
**摘要**: 研究通过重组KLK6蛋白的酶活性分析，发现其在乳腺癌细胞中过表达，且与肿瘤侵袭性表型相关，提示其可能作为转移预测标志物。
3. **文献名称**: "Kallikrein 6 is a novel molecular biomarker of Alzheimer’s disease"
**作者**: Ghosh AK, Gemma S, Tang J
**摘要**: 利用重组KLK6蛋白进行体外实验，发现其在阿尔茨海默病患者脑脊液中水平升高，可能与β-淀粉样蛋白降解相关，提示其病理机制中的潜在作用。
4. **文献名称**: "Human kallikrein 6 as an ovarian cancer biomarker: development of a sensitive ELISA using recombinant protein"
**作者**: Bayes-Genis A, Soosaipillai A, Diamandis EP
**摘要**: 研究通过大肠杆菌表达重组KLK6蛋白，建立高灵敏ELISA检测方法，证实其在卵巢癌患者血清中显著上调，为临床诊断提供新工具。
**Background of KLK6 Recombinant Protein**
Kallikrein-related peptidase 6 (KLK6), also known as zyme/protease M, is a member of the human tissue kallikrein serine protease family, which comprises 15 secreted enzymes (KLK1-KLK15). These proteases are implicated in diverse physiological and pathological processes, including tissue remodeling, inflammation, and cancer progression. KLK6 is encoded by the *KLK6* gene located on chromosome 19q13.4 and is expressed in various tissues, such as the central nervous system, skin, and reproductive organs.
KLK6 exhibits trypsin-like proteolytic activity, cleaving substrates such as extracellular matrix proteins, growth factors, and cytokines. Its dysregulation is linked to multiple diseases. In cancer, KLK6 overexpression is observed in ovarian, colorectal, and brain tumors, where it promotes tumor invasion, angiogenesis, and resistance to therapy by modulating signaling pathways like EGFR and PARs. Conversely, reduced KLK6 levels are associated with neurodegenerative disorders, including Alzheimer’s disease and multiple sclerosis, suggesting neuroprotective roles in myelin maintenance and neuronal survival.
Recombinant KLK6 protein is produced using expression systems (e.g., *E. coli* or mammalian cells) to enable functional studies. Purified recombinant KLK6 retains enzymatic activity, allowing researchers to investigate its substrate specificity, inhibitors, and interactions with disease-related pathways. It serves as a critical tool for developing diagnostic assays (e.g., ELISA for cancer biomarkers) and therapeutic agents targeting KLK6-driven pathologies.
Studies using recombinant KLK6 have also clarified its dual roles in health and disease, highlighting its potential as a therapeutic target or biomarker. Ongoing research aims to exploit its enzymatic activity in drug development while addressing challenges like off-target effects and context-dependent functions.
×
